Anika Therapeutics
32 Wiggins Avenue
Bedford
Massachusetts
01730
United States
Tel: 781-457-9000
Fax: 781-935-4120
Website: http://www.anikatherapeutics.com/
About Anika Therapeutics
Anika Therapeutics is a pioneer in developing therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body. HA enhances joint function and coats, protects, cushions and lubricates soft tissues. HA also is present in the skin, where it supports skin structure and elasticity. With more than 20 years of experience in HA technology, Anika is recognized worldwide as a provider of premium HA products that are effective, safe and long-lasting. Anika manufactures and distributes a diverse portfolio of HA-based products that cover a broad range of therapeutic applications. These products include ORTHOVISC®, ORTHOVISC® mini, and MONOVISC™ used in the treatment of osteoarthritis; HYVISC® used in the treatment of equine osteoarthritis; the ELEVESS™ family of cosmetic dermatology products for facial wrinkles, scar remediation and lip augmentation; AMVISC®, AMVISC® Plus, STAARVISC™ II, and OPTIVISC™ injectable viscoelastic HA products for ophthalmic surgery; INCERT®, an HA-based anti-adhesive for surgical applications; and next-generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA.329 articles about Anika Therapeutics
-
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
4/18/2024
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of the market on Wednesday, May 8, 2024 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.
-
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/2/2024
Anika Therapeutics, Inc. today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024.
-
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
3/13/2024
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its fourth quarter and full year ended December 31, 2023.
-
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 08, 2024
3/8/2024
Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that on March 1, 2024, Anika granted non-statutory stock options covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.14, which equaled the closing price of common stock on the Nasdaq Global Select Market on the grant date, to one newly hired non-executive employee.
-
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
2/27/2024
Anika Therapeutics, Inc. announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
-
Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting
2/13/2024
Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced it is highlighting recently-launched products in high growth segments of joint preservation and restoration from its Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions businesses during the 2024 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting on February 13-15 in San Francisco, CA.
-
Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
11/28/2023
Anika Therapeutics, Inc. today announced that the first surgeries using the Integrity Implant System were successfully performed by Dr. Christopher Baker at the Florida Orthopaedic Institute in Tampa, FL.
-
Anika to Participate in Upcoming November 2023 Investor Conferences
11/7/2023
Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will be participating at the following investor conferences.
-
Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business
11/2/2023
Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, reported financial results for its third quarter ended September 30, 2023.
-
Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023
10/10/2023
Anika Therapeutics, Inc. announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.
-
Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting
9/19/2023
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, today announced the full market release of their RevoMotion Reverse Shoulder Arthroplasty System (RSA) at the 2023 Orthopaedic Summit (OSET) Annual Meeting on September 20-23 in Boston, MA.
-
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 15, 2023
9/15/2023
Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that on September 5, 2023, Anika granted restricted stock units covering 10,000 shares of common stock to one newly hired non-executive employee.
-
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference - September 12, 2023
9/12/2023
Anika Therapeutics, Inc. today announced that management will participate in the Sidoti Small Cap Virtual Investor Conference on Thursday, September 21, 2023.
-
Anika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs
8/17/2023
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the final 510(k) clearance from the FDA for the Integrity™ Implant System.
-
Anika Reports Second Quarter 2023 Financial Results
8/8/2023
Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, reported financial results for its second quarter ended June 30, 2023.
-
Anika to Issue Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
7/20/2023
Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second quarter 2023 financial results after the close of the market on Tuesday, August 8, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
-
Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting
7/12/2023
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced it will highlight core products from its joint preservation and restoration portfolio at the 2023 American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting on July 13-16th in Washington, D.C.
-
Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone
5/30/2023
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has completed enrollment of the pivotal Phase III clinical study for Hyalofast (Hyalofast 15-01) on its path to achieving FDA approval in the United States.
-
Anika Reports First Quarter 2023 Financial Results
5/9/2023
Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, reported financial results for its first quarter ended March 31, 2023.
-
Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023
4/19/2023
Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first quarter 2023 financial results after the close of the market on Tuesday, May 9, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.